Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulforaphane
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Publication Of Data On SFX-01 In Glioblastoma
Details : The in vitro data, in GBM cells and patient-derived glioma-initiating cells, show anti-tumour activity of the Company's lead asset SFX-01. In both models, SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved surv...
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2021
Lead Product(s) : Sulforaphane
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $15.3 million
Deal Type : Public Offering
Evgen Pharma Announces Placing and Open Offer to raise up to £11 million
Details : The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2021
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $15.3 million
Deal Type : Public Offering
Lead Product(s) : Sulforaphane
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Evgen Pharma Announces Positive Pre-Clinical Data in Glioma for Lead Asset SFX-01
Details : The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times.
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 21, 2021
Lead Product(s) : Sulforaphane
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : University of Dundee
Deal Size : Not Applicable
Deal Type : Not Applicable
Evgen Pharma Provides Patient Recruitment Update in STAR-COVID 19 Trial
Details : A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2021
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : University of Dundee
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sulforaphane
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Evgen Pharma Recruits First Patient in STAR Trial
Details : This Phase II/III trial will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for s...
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2020
Lead Product(s) : Sulforaphane
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SFX-01
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Recipient : University of Rochester School of Medicine & Dentistry
Deal Size : Undisclosed
Deal Type : Partnership
Evgen and Rochester University partner to advance SFX-01 trial
Details : Under the agreement, Evgen will supply SFX-01 to support a potential future clinical trial led by University of Rochester Nephrology division chief Thu Le.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 18, 2020
Lead Product(s) : SFX-01
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Recipient : University of Rochester School of Medicine & Dentistry
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?